Altered pharmacokinetics of enrofloxacin in experimental models of hepatic and renal impairment.
Vet Res Commun
; 33(5): 481-7, 2009 Jun.
Article
em En
| MEDLINE
| ID: mdl-19085067
ABSTRACT
We investigated the effects of hepatic and renal impairment on the pharmacokinetics of enrofloxacin in Sprague-Dawley rats. Experimental hepatic and renal failure were induced by carbon tetrachloride (CCL(4)) and 5/6 nephrectomy, respectively. After intravenous dosing of enrofloxacin (10 mg/kg), plasma concentrations of enrofloxacin were measured using liquid chromatograph/mass spectrometry. There was no significant effect of hepatic impairment on enrofloxacin pharmacokinetics. However, renal impairment markedly prolonged elimination half life (t(1/2lambdaz)) of enrofloxacin (P < 0.05), comparing with respective control. Total body clearance (Cl(b)) and volume of distribution at steady state (V(ss)) were significantly decreased (P < 0.05) by renal impairment. In conclusion, these results suggested that renal impairment could affect the pharmacokinetics of enrofloxacin.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Falência Hepática
/
Fluoroquinolonas
/
Insuficiência Renal
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article